Aida Pharmaceuticals, Inc.
AIDA · OTC
9/30/2008 | 6/30/2008 | 3/31/2008 | 12/31/2007 | |
|---|---|---|---|---|
| Revenue | $12 | $11 | $8 | $11 |
| % Growth | 9% | 42.4% | -27.2% | – |
| Cost of Goods Sold | $5 | $5 | $4 | $5 |
| Gross Profit | $7 | $6 | $4 | $6 |
| % Margin | 58.3% | 56.6% | 51.6% | 54.6% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $4 | $12 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$13 | $0 | $0 |
| Operating Expenses | $4 | -$0 | $3 | $2 |
| Operating Income | $3 | $6 | $1 | $3 |
| % Margin | 21.3% | 59.4% | 8.9% | 31% |
| Other Income/Exp. Net | -$1 | -$14 | -$0 | -$2 |
| Pre-Tax Income | $2 | -$7 | $0 | $1 |
| Tax Expense | -$1 | -$0 | $0 | $0 |
| Net Income | $2 | -$7 | -$0 | $2 |
| % Margin | 19.3% | -62.1% | -0.2% | 22.9% |
| EPS | 0.08 | -0.25 | -0.001 | 0.09 |
| % Growth | 132% | -35,614.3% | -100.8% | – |
| EPS Diluted | 0.08 | -0.25 | -0.001 | 0.09 |
| Weighted Avg Shares Out | 27 | 27 | 27 | 27 |
| Weighted Avg Shares Out Dil | 27 | 27 | 27 | 27 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $1 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $0 |
| EBITDA | $3 | -$6 | $1 | $4 |
| % Margin | 28.2% | -53.1% | 15.5% | 35.4% |